Stereotactic ablative radiotherapy (SABR), historically known as stereotactic body radiation therapy (SBRT), has rapidly developed into an important tool radiation oncologists use in the treatment of lung cancers. The indications for treatment of medically inoperable lung cancers have become well established. SABR is also being evaluated more frequently in the setting of operable lung cancers, metastases from primary tumors to the lungs and other anatomic sites, and oligometastatic lung disease as well. This chapter highlights the biologic, technologic, and clinical advances that have led to the increased acceptance and use of SABR in mainstream radiation oncology practices for lung cancer.
- Lung cancer
- Stereotactic ablative radiotherapy
- Stereotactic body radiation therapy
ASJC Scopus subject areas